Documents

MEB 14: Parallel importation: marketing authorisation and maintenance

Parallel import is the importation – and subsequent marketing in the Netherlands – of a medicinal product authorised elsewhere in ...

Policy document | 27-05-2020

Strategic Business Plan 2020-2024

This Strategic Business Plan (SBP) describes the strategic direction of the Medicines Evaluation Board (MEB) in the coming period ...

Publication | 21-04-2020

MEB 13: Nomenclature of pharmaceutical products

This document describes the requirements which the marketing authorisation holder has to fulfil when submitting a proposal for a ...

Policy document | 23-03-2020

MEB 6: Labelling of pharmaceutical products

The presentation of the primary and secondary packaging of a medicinal product are determining factors in the recognition of a ...

Policy document | 23-03-2020

MEB Science Day 2020 - Presentation Fiona Sewell

Publication | 04-03-2020

MEB Science Day 2020 - Presentation Coenraad Hendriksen

Publication | 04-03-2020

MEB Science Day 2020 - Presentation Coen Stalpers

Publication | 04-03-2020

MEB Science Day 2020 - Presentation Roos Masereeuw

Publication | 04-03-2020

MEB Science Day 2020 - Presentation Peter van Meer

Publication | 13-02-2020

MEB 44: Direct Healthcare Professional Communications (DHPCs)

This document is based on the Guideline on Good Pharmacovigilance Practices (GVP) Module XV – Safety communication, and is aimed ...

Policy document | 20-01-2020